acquired partial lipodystrophy

In general, treatment for acquired partial lipodystrophy is limited to cosmetic, dietary, or medical options.

This condition is responsible for most recurrent hospital admissions in patients with acquired partial lipodystrophy.

In 2006, lamin B2 missense mutations were identified in patients with acquired partial lipodystrophy.

Acquired partial lipodystrophy (Barraquer-Simons syndrome)

-Membranoproliferative glomerulonephritis and the presence of renal dysfunction largely determine the prognosis of acquired partial lipodystrophy.

-The course of membranoproliferative glomerulonephritis in acquired partial lipodystrophy has not been significantly altered by treatment with corticosteroids or cytotoxic medications.

Several case reports have revealed an association between acquired partial lipodystrophy and other diseases (see the list of disorders associated with acquired partial lipodystrophy).

A single report has suggested a beneficial effect from treatment with rosiglitazone on fat distribution in acquired partial lipodystrophy ; however, preferential fat gain was in the lower body.

-Antinuclear antibodies (ANA) and anti-double-stranded deoxyribonucleic acid (DNA) antibodies have reportedly been observed in some patients with acquired partial lipodystrophy.